Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 May;84(10):1330–1338. doi: 10.1054/bjoc.2001.1808

Bladder cancer cells acquire competent mechanisms to escape Fas-mediated apoptosis and immune surveillance in the course of malignant transformation

F G E Perabo 1, S Kamp 1, D Schmidt 1, H Lindner 1, G Steiner 1, R H Mattes 2, A Wirger 3, K Pegelow 4, P Albers 1, E C Kohn 5, A von Ruecker 4, S C Mueller 1
PMCID: PMC2363638  PMID: 11355943

Abstract

Mechanisms of resistance against Fas-mediated cell killing have been reported in different malignancies. However, the biological response of immune escape mechanisms might depend on malignant transformation of cancer cells. In this study we investigated different mechanisms of immune escape in 2 well-differentiated low-grade (RT4 and RT112) and 2 poorly differentiated high-grade (T24 and TCCSUP) bladder cancer cell lines. Fas, the receptor of Fas-ligand, is expressed and shedded by human transitional bladder carcinoma cell lines RT4, RT112, T24 and TCCSUP. Cytotoxicity and apoptosis assays demonstrate that in spite of the Fas expression, poorly differentiated T24 and TCCSUP cells are insensitive towards either recombinant Fas-ligand or agonistic apoptosis-inducing monoclonal antibody against Fas. In poorly differentiated T24 and TCCSUP cell lines we were able to detect marked Fas-ligand protein by flow cytometry and Western blot analysis. In grade 1 RT4 and RT112 cells only minor expression of Fas-ligand possibly because of proteinase action. Fas-ligand mRNA translation or post-translational processing seems to be regulated differentially in the cancer cell lines depending on malignant transformation. In co-culture experiments we show that poorly differentiated cells can induce apoptosis and cell death in Jurkat cells and activated peripheral blood mononuclear cells. This in vitro study suggests that bladder cancer cells can take advantage of different mechanisms of immune evasion and become more competent in avoiding immune surveillance during transformation to higher-grade malignant disease. © 2001 Cancer Research Campaign www.bjcancer.com

Keywords: bladder cancer, Fas, Fas-ligand, apoptosis, immune escape

Full Text

The Full Text of this article is available as a PDF (310.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alderson M. R., Tough T. W., Davis-Smith T., Braddy S., Falk B., Schooley K. A., Goodwin R. G., Smith C. A., Ramsdell F., Lynch D. H. Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med. 1995 Jan 1;181(1):71–77. doi: 10.1084/jem.181.1.71. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Arase H., Arase N., Saito T. Fas-mediated cytotoxicity by freshly isolated natural killer cells. J Exp Med. 1995 Mar 1;181(3):1235–1238. doi: 10.1084/jem.181.3.1235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bamberger A. M., Schulte H. M., Thuneke I., Erdmann I., Bamberger C. M., ASA S. L. Expression of the apoptosis-inducing Fas ligand (FasL) in human first and third trimester placenta and choriocarcinoma cells. J Clin Endocrinol Metab. 1997 Sep;82(9):3173–3175. doi: 10.1210/jcem.82.9.4360. [DOI] [PubMed] [Google Scholar]
  4. Cascino I., Fiucci G., Papoff G., Ruberti G. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J Immunol. 1995 Mar 15;154(6):2706–2713. [PubMed] [Google Scholar]
  5. Cheng J., Zhou T., Liu C., Shapiro J. P., Brauer M. J., Kiefer M. C., Barr P. J., Mountz J. D. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science. 1994 Mar 25;263(5154):1759–1762. doi: 10.1126/science.7510905. [DOI] [PubMed] [Google Scholar]
  6. Chicheportiche Y., Bourdon P. R., Xu H., Hsu Y. M., Scott H., Hession C., Garcia I., Browning J. L. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem. 1997 Dec 19;272(51):32401–32410. doi: 10.1074/jbc.272.51.32401. [DOI] [PubMed] [Google Scholar]
  7. Crowe D. L., Boardman M. L., Fong K. S. Anti-Fas antibody differentially regulates apoptosis in Fas ligand resistant carcinoma lines via the caspase 3 family of cell death proteases but independently of bcl2 expression. Anticancer Res. 1998 Sep-Oct;18(5A):3163–3170. [PubMed] [Google Scholar]
  8. Dhein J., Walczak H., Bäumler C., Debatin K. M., Krammer P. H. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95) Nature. 1995 Feb 2;373(6513):438–441. doi: 10.1038/373438a0. [DOI] [PubMed] [Google Scholar]
  9. Ding E. X., Hizuta A., Morimoto Y., Tanida T., Hongo T., Ishii T., Yamano T., Fujiwara T., Iwagaki H., Tanaka N. Human colon cancer cells express the functional Fas ligand. Res Commun Mol Pathol Pharmacol. 1998 Jul;101(1):13–24. [PubMed] [Google Scholar]
  10. Gastman B. R., Atarshi Y., Reichert T. E., Saito T., Balkir L., Rabinowich H., Whiteside T. L. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res. 1999 Oct 15;59(20):5356–5364. [PubMed] [Google Scholar]
  11. Gratas C., Tohma Y., Barnas C., Taniere P., Hainaut P., Ohgaki H. Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer. Cancer Res. 1998 May 15;58(10):2057–2062. [PubMed] [Google Scholar]
  12. Gratas C., Tohma Y., Van Meir E. G., Klein M., Tenan M., Ishii N., Tachibana O., Kleihues P., Ohgaki H. Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors. Brain Pathol. 1997 Jul;7(3):863–869. doi: 10.1111/j.1750-3639.1997.tb00889.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Griffith T. S., Yu X., Herndon J. M., Green D. R., Ferguson T. A. CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance. Immunity. 1996 Jul;5(1):7–16. doi: 10.1016/s1074-7613(00)80305-2. [DOI] [PubMed] [Google Scholar]
  14. Gruss H. J. Molecular, structural, and biological characteristics of the tumor necrosis factor ligand superfamily. Int J Clin Lab Res. 1996;26(3):143–159. doi: 10.1007/BF02592977. [DOI] [PubMed] [Google Scholar]
  15. Hahne M., Rimoldi D., Schröter M., Romero P., Schreier M., French L. E., Schneider P., Bornand T., Fontana A., Lienard D. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science. 1996 Nov 22;274(5291):1363–1366. doi: 10.1126/science.274.5291.1363. [DOI] [PubMed] [Google Scholar]
  16. Irmler M., Thome M., Hahne M., Schneider P., Hofmann K., Steiner V., Bodmer J. L., Schröter M., Burns K., Mattmann C. Inhibition of death receptor signals by cellular FLIP. Nature. 1997 Jul 10;388(6638):190–195. doi: 10.1038/40657. [DOI] [PubMed] [Google Scholar]
  17. Itoh N., Tsujimoto Y., Nagata S. Effect of bcl-2 on Fas antigen-mediated cell death. J Immunol. 1993 Jul 15;151(2):621–627. [PubMed] [Google Scholar]
  18. Kayagaki N., Kawasaki A., Ebata T., Ohmoto H., Ikeda S., Inoue S., Yoshino K., Okumura K., Yagita H. Metalloproteinase-mediated release of human Fas ligand. J Exp Med. 1995 Dec 1;182(6):1777–1783. doi: 10.1084/jem.182.6.1777. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Klas C., Debatin K. M., Jonker R. R., Krammer P. H. Activation interferes with the APO-1 pathway in mature human T cells. Int Immunol. 1993 Jun;5(6):625–630. doi: 10.1093/intimm/5.6.625. [DOI] [PubMed] [Google Scholar]
  20. Kägi D., Vignaux F., Ledermann B., Bürki K., Depraetere V., Nagata S., Hengartner H., Golstein P. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science. 1994 Jul 22;265(5171):528–530. doi: 10.1126/science.7518614. [DOI] [PubMed] [Google Scholar]
  21. Lee S. H., Lee J. Y., Park W. S., Kim S. Y., Jang J. J., Yoo N. J. Transitional cell carcinoma expresses high levels of Fas ligand in vivo. BJU Int. 1999 Apr;83(6):698–702. doi: 10.1046/j.1464-410x.1999.00975.x. [DOI] [PubMed] [Google Scholar]
  22. Liu C., Cheng J., Mountz J. D. Differential expression of human Fas mRNA species upon peripheral blood mononuclear cell activation. Biochem J. 1995 Sep 15;310(Pt 3):957–963. doi: 10.1042/bj3100957. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Midis G. P., Shen Y., Owen-Schaub L. B. Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy. Cancer Res. 1996 Sep 1;56(17):3870–3874. [PubMed] [Google Scholar]
  24. Mitsiades N., Poulaki V., Kotoula V., Leone A., Tsokos M. Fas ligand is present in tumors of the Ewing's sarcoma family and is cleaved into a soluble form by a metalloproteinase. Am J Pathol. 1998 Dec;153(6):1947–1956. doi: 10.1016/S0002-9440(10)65708-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Mizutani Y., Yoshida O., Bonavida B. Prognostic significance of soluble Fas in the serum of patients with bladder cancer. J Urol. 1998 Aug;160(2):571–576. [PubMed] [Google Scholar]
  26. Mizutani Y., Yoshida O., Miki T. Adriamycin-mediated potentiation of cytotoxicity against freshly isolated bladder cancer cells by autologous non-activated peripheral blood lymphocytes and tumor infiltrating lymphocytes. J Urol. 1999 Dec;162(6):2170–2175. doi: 10.1016/S0022-5347(05)68154-2. [DOI] [PubMed] [Google Scholar]
  27. Moers C., Warskulat U., Müschen M., Even J., Niederacher D., Josien R., Koldovsky U., Beckmann M. W., Häussinger D. Regulation of CD95 (Apo-1/Fas) ligand and receptor expression in squamous-cell carcinoma by interferon-gamma and cisplatin. Int J Cancer. 1999 Feb 9;80(4):564–572. doi: 10.1002/(sici)1097-0215(19990209)80:4<564::aid-ijc14>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  28. Müschen M., Moers C., Warskulat U., Niederacher D., Betz B., Even J., Lim A., Josien R., Beckmann M. W., Häussinger D. CD95 ligand expression in dedifferentiated breast cancer. J Pathol. 1999 Nov;189(3):378–386. doi: 10.1002/(SICI)1096-9896(199911)189:3<378::AID-PATH439>3.0.CO;2-D. [DOI] [PubMed] [Google Scholar]
  29. Nagata S. Apoptosis by death factor. Cell. 1997 Feb 7;88(3):355–365. doi: 10.1016/s0092-8674(00)81874-7. [DOI] [PubMed] [Google Scholar]
  30. Nakamura S., Takeshima M., Nakamura Y., Ohtake S., Matsuda T. Induction of apoptosis in HL60 leukemic cells by anticancer drugs in combination with anti-Fas monoclonal antibody. Anticancer Res. 1997 Jan-Feb;17(1A):173–179. [PubMed] [Google Scholar]
  31. Natoli G., Ianni A., Costanzo A., De Petrillo G., Ilari I., Chirillo P., Balsano C., Levrero M. Resistance to Fas-mediated apoptosis in human hepatoma cells. Oncogene. 1995 Sep 21;11(6):1157–1164. [PubMed] [Google Scholar]
  32. Niehans G. A., Brunner T., Frizelle S. P., Liston J. C., Salerno C. T., Knapp D. J., Green D. R., Kratzke R. A. Human lung carcinomas express Fas ligand. Cancer Res. 1997 Mar 15;57(6):1007–1012. [PubMed] [Google Scholar]
  33. O'Connell J., O'Sullivan G. C., Collins J. K., Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med. 1996 Sep 1;184(3):1075–1082. doi: 10.1084/jem.184.3.1075. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Ogasawara J., Watanabe-Fukunaga R., Adachi M., Matsuzawa A., Kasugai T., Kitamura Y., Itoh N., Suda T., Nagata S. Lethal effect of the anti-Fas antibody in mice. Nature. 1993 Aug 26;364(6440):806–809. doi: 10.1038/364806a0. [DOI] [PubMed] [Google Scholar]
  35. Owen-Schaub L. B., Angelo L. S., Radinsky R., Ware C. F., Gesner T. G., Bartos D. P. Soluble Fas/APO-1 in tumor cells: a potential regulator of apoptosis? Cancer Lett. 1995 Jul 20;94(1):1–8. doi: 10.1016/0304-3835(95)03834-j. [DOI] [PubMed] [Google Scholar]
  36. Owen-Schaub L. B., Radinsky R., Kruzel E., Berry K., Yonehara S. Anti-Fas on nonhematopoietic tumors: levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness. Cancer Res. 1994 Mar 15;54(6):1580–1586. [PubMed] [Google Scholar]
  37. Powell W. C., Fingleton B., Wilson C. L., Boothby M., Matrisian L. M. The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis. Curr Biol. 1999 Dec 16;9(24):1441–1447. doi: 10.1016/s0960-9822(00)80113-x. [DOI] [PubMed] [Google Scholar]
  38. Runic R., Lockwood C. J., Ma Y., Dipasquale B., Guller S. Expression of Fas ligand by human cytotrophoblasts: implications in placentation and fetal survival. J Clin Endocrinol Metab. 1996 Aug;81(8):3119–3122. doi: 10.1210/jcem.81.8.8768884. [DOI] [PubMed] [Google Scholar]
  39. Schulze-Osthoff K., Ferrari D., Los M., Wesselborg S., Peter M. E. Apoptosis signaling by death receptors. Eur J Biochem. 1998 Jun 15;254(3):439–459. doi: 10.1046/j.1432-1327.1998.2540439.x. [DOI] [PubMed] [Google Scholar]
  40. Strand S., Hofmann W. J., Hug H., Müller M., Otto G., Strand D., Mariani S. M., Stremmel W., Krammer P. H., Galle P. R. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells--a mechanism of immune evasion? Nat Med. 1996 Dec;2(12):1361–1366. doi: 10.1038/nm1296-1361. [DOI] [PubMed] [Google Scholar]
  41. Suda T., Hashimoto H., Tanaka M., Ochi T., Nagata S. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J Exp Med. 1997 Dec 15;186(12):2045–2050. doi: 10.1084/jem.186.12.2045. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Suda T., Takahashi T., Golstein P., Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell. 1993 Dec 17;75(6):1169–1178. doi: 10.1016/0092-8674(93)90326-l. [DOI] [PubMed] [Google Scholar]
  43. Tamm I., Wang Y., Sausville E., Scudiero D. A., Vigna N., Oltersdorf T., Reed J. C. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 1998 Dec 1;58(23):5315–5320. [PubMed] [Google Scholar]
  44. Tanaka M., Suda T., Takahashi T., Nagata S. Expression of the functional soluble form of human fas ligand in activated lymphocytes. EMBO J. 1995 Mar 15;14(6):1129–1135. doi: 10.1002/j.1460-2075.1995.tb07096.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Thilenius A. R., Braun K., Russell J. H. Agonist antibody and Fas ligand mediate different sensitivity to death in the signaling pathways of Fas and cytoplasmic mutants. Eur J Immunol. 1997 May;27(5):1108–1114. doi: 10.1002/eji.1830270510. [DOI] [PubMed] [Google Scholar]
  46. Ungefroren H., Voss M., Jansen M., Roeder C., Henne-Bruns D., Kremer B., Kalthoff H. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis. Cancer Res. 1998 Apr 15;58(8):1741–1749. [PubMed] [Google Scholar]
  47. Wang J., Lenardo M. J. Molecules involved in cell death and peripheral tolerance. Curr Opin Immunol. 1997 Dec;9(6):818–825. doi: 10.1016/s0952-7915(97)80184-7. [DOI] [PubMed] [Google Scholar]
  48. Weller M., Malipiero U., Aguzzi A., Reed J. C., Fontana A. Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J Clin Invest. 1995 Jun;95(6):2633–2643. doi: 10.1172/JCI117965. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Yamaguchi K., Nagai S., Ninomiya-Tsuji J., Nishita M., Tamai K., Irie K., Ueno N., Nishida E., Shibuya H., Matsumoto K. XIAP, a cellular member of the inhibitor of apoptosis protein family, links the receptors to TAB1-TAK1 in the BMP signaling pathway. EMBO J. 1999 Jan 4;18(1):179–187. doi: 10.1093/emboj/18.1.179. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. von Bernstorff W., Spanjaard R. A., Chan A. K., Lockhart D. C., Sadanaga N., Wood I., Peiper M., Goedegebuure P. S., Eberlein T. J. Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas (APO-1/CD95) receptors and aberrant expression of functional Fas ligand. Surgery. 1999 Jan;125(1):73–84. doi: 10.1067/msy.2099.93570. [DOI] [PubMed] [Google Scholar]
  51. von Reyher U., Sträter J., Kittstein W., Gschwendt M., Krammer P. H., Möller P. Colon carcinoma cells use different mechanisms to escape CD95-mediated apoptosis. Cancer Res. 1998 Feb 1;58(3):526–534. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES